A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Latest Information Update: 29 Jul 2024
Price :
$35 *
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Sponsors Sanofi
- 15 Dec 2023 Planned End Date changed from 11 Apr 2025 to 30 Mar 2026.
- 15 Dec 2023 Planned primary completion date changed from 11 Apr 2025 to 30 Mar 2026.
- 12 Dec 2022 Planned End Date changed from 12 Nov 2024 to 11 Apr 2025.